<DOC>
	<DOCNO>NCT00649792</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability activity Fampridine-SR administer 36 additional month patient previously participate MS-F204 study become commercially available , whichever come first .</brief_summary>
	<brief_title>Open-Label Extension Study Evaluate Safety , Tolerability Activity Oral Fampridine-SR Patients With Multiple Sclerosis Who Participated MS-F204 Trial</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) disorder body 's immune system affect central nervous system ( CNS ) . Normally , nerve fiber carry electrical impulse spinal cord , provide communication brain arm legs . In people MS , fatty sheath surround insulate nerve fiber ( call `` myelin '' ) deteriorate , cause nerve impulse slow stopped . As result , patient MS may experience period muscle weakness symptom numbness , loss vision , loss coordination , paralysis , spasticity , mental physical fatigue decrease ability think and/or remember . These period illness may come ( exacerbation ) go ( remission ) . Fampridine-SR experimental drug report possibly improve muscle strength walk ability people MS . This study evaluate effect possible risk take Fampridine-SR MS patient long period time .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Patient must previously enrol Acorda Therapeutics MSF204 study receive either FampridineSR placebo Patient clinically define multiple sclerosis ( diagnostic criterion base : McDonald WI , et al . Recommended Diagnostic Criteria Multiple Sclerosis : Guidelines International Panel Diagnosis Multiple Sclerosis . Annals Neurology . 2001 ; 50 : 121127 ) Patient must least 18 year age . Any patient age 70 must good overall health judgment investigator Patient must adequate cognitive function , judge Investigator Patients woman childbearing potential must negative urine pregnancy test screen visit Female patient either pregnant breastfeeding . Women childbearing potential use specified birth control method Patients discontinue prematurely MSF204 study Patients history seizure evidence past , possible epileptiform activity EEG Patient either clinically significant abnormal ECG laboratory value MSF204 EXT screen visit Patient severe renal impairment Patient angina , uncontrolled hypertension , clinically significant cardiac arrhythmia , clinically significant cardiovascular abnormality , judge Investigator Patient know allergy pyridinecontaining substance inactive ingredient FampridineSR tablet Patient receive investigational drug ( FampridineSR placebo MSF204 study ) within 30 day MSF204EXT screen visit patient schedule enroll investigational drug trial time study Patient history drug alcohol abuse within past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>walk</keyword>
	<keyword>leg strength</keyword>
	<keyword>demyelination</keyword>
</DOC>